Dynatrace Inc. Common Stock vs Personalis Inc. Common Stock — how do they compare? Dynatrace Inc. Common Stock trades at $63.33 (market cap $18.63B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: Dynatrace Inc. Common Stock is far larger — about 11× Personalis Inc. Common Stock's market cap, and Dynatrace Inc. Common Stock is trading nearer its 52-week high, Personalis Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 3 Days and Personalis Inc. Common Stock for 0 Days on average.
| DT | PSNL | |
|---|---|---|
Market Cap | $18.63B | $1.69B |
Volume | 8,438,411 | 3,817,236 |
Sector | Technology | Health |
52-Week High | $65.25 | $18.38 |
52-Week Low | $32.36 | $5.04 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $17.68B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
Dynatrace (DT) trades at $64.46, down 1.21% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported robust revenue growth to $1.70B in 2025 and has consistently beaten earnings estimates, though its valuation ratios like a P/E of 128.94 are elevated. Recent developments include achieving FedRAMP certification and completing the acquisition of Arize, enhancing its AI observability platform.
The outlook is positive given strong analyst support (85.71% buy ratings) and a consensus price target of $62.44, though risks include high valuation sensitivity and projected net income decline in 2026. Earnings growth and federal market expansion are key catalysts, but investors should monitor execution against lofty expectations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →